← FDA DRUG APPROVALS

FDA ANDA · ANDA072319

GLYCOPREP

Sponsor: GOLDLINE

APPLICATION
ANDA072319
TYPE
ANDA
ORIGINAL APPROVAL
1988-12-23
LATEST ACTION
1988-12-23
ROUTE
ORAL
DOSAGE FORM
FOR SUSPENSION
MARKETING STATUS
Discontinued

Products

GLYCOPREPDiscontinued
POLYETHYLENE GLYCOL 3350 236GM/BOT, POTASSIUM CHLORIDE 2.97GM/BOT, SODIUM BICARBONATE 6.74GM/BOT, SODIUM CHLORIDE 5.86GM/BOT, SODIUM SULFATE ANHYDROUS 22.74GM/BOT · FOR SUSPENSION · ORAL

Approval history

1988-12-23OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →